Title:
HIGH-ACTIVITY HPK1 KINASE INHIBITOR
Document Type and Number:
WIPO Patent Application WO/2022/214009
Kind Code:
A1
Abstract:
Provided are a compound, which has a structure of formula (I) and is capable of inhibiting HPK1 kinase activity, and a pharmaceutical composition comprising the compound. Further provided is the use of the compound in the prevention and/or treatment of cancers, tumors, inflammatory diseases, autoimmune diseases or immune-mediated diseases.
More Like This:
Inventors:
CHEN YUFENG (CN)
SHI YONGQIANG (CN)
WU PENG (CN)
WEN QIAODONG (CN)
YANG HAN (CN)
LV MENG (CN)
LIU CANFENG (CN)
CHEN KAIXUAN (CN)
WANG YOUPING (CN)
HE NANHAI (CN)
SHI YONGQIANG (CN)
WU PENG (CN)
WEN QIAODONG (CN)
YANG HAN (CN)
LV MENG (CN)
LIU CANFENG (CN)
CHEN KAIXUAN (CN)
WANG YOUPING (CN)
HE NANHAI (CN)
Application Number:
PCT/CN2022/085446
Publication Date:
October 13, 2022
Filing Date:
April 07, 2022
Export Citation:
Assignee:
ADLAI NORTYE BIOPHARMA CO LTD (CN)
International Classes:
C07D239/48; A61K31/506; A61P35/00
Domestic Patent References:
| WO2004056807A1 | 2004-07-08 |
Foreign References:
| CN112243439A | 2021-01-19 | |||
| CN1665789A | 2005-09-07 | |||
| CN110678466A | 2020-01-10 | |||
| US20050256111A1 | 2005-11-17 |
Attorney, Agent or Firm:
UNITALEN ATTORNEYS AT LAW (CN)
Download PDF: